113 related articles for article (PubMed ID: 27059001)
21. Effect of Sirolimus/Metformin Co-Treatment on Hyperglycemia and Cellular Respiration in BALB/c Mice.
Albawardi A; Saraswathiamma D; Sharma C; Elomami A; Souid AK; Almarzooqi S
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674739
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
23. DPP IV inhibitor treatment attenuates bone loss and improves mechanical bone strength in male diabetic rats.
Glorie L; Behets GJ; Baerts L; De Meester I; D'Haese PC; Verhulst A
Am J Physiol Endocrinol Metab; 2014 Sep; 307(5):E447-55. PubMed ID: 25053403
[TBL] [Abstract][Full Text] [Related]
24. Effects of the combination of dipeptidyl peptidase-IV inhibitor ASP8497 and antidiabetic drugs in streptozotocin-nicotinamide-induced mildly diabetic mice.
Tahara A; Matsuyama-Yokono A; Nakano R; Someya Y; Hayakawa M; Shibasaki M
Eur J Pharmacol; 2009 Mar; 605(1-3):170-6. PubMed ID: 19171131
[TBL] [Abstract][Full Text] [Related]
25. Improved outcome of islet transplantation in partially pancreatectomized diabetic mice by inhibition of dipeptidyl peptidase-4 with sitagliptin.
Kim YS; Oh SH; Park KS; No H; Oh BJ; Kim SK; Jung HS; Kim JH; Lee MS; Lee MK; Kim KW
Pancreas; 2011 Aug; 40(6):855-60. PubMed ID: 21747318
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and anti-diabetic activity of triazolotriazine derivatives as dipeptidyl peptidase-4 (DPP-4) inhibitors.
Patel BD; Bhadada SV; Ghate MD
Bioorg Chem; 2017 Jun; 72():345-358. PubMed ID: 28302310
[TBL] [Abstract][Full Text] [Related]
27. Metformin improves immunosuppressant induced hyperglycemia and exocrine apoptosis in rats.
Shivaswamy V; Bennett RG; Clure CC; Larsen JL; Hamel FG
Transplantation; 2013 Jan; 95(2):280-4. PubMed ID: 23250335
[TBL] [Abstract][Full Text] [Related]
28. Gemigliptin suppresses salivary dysfunction in streptozotocin-induced diabetic rats.
Kang WS; Jung WK; Park SB; Kim HR; Kim J
Biomed Pharmacother; 2021 May; 137():111297. PubMed ID: 33493968
[TBL] [Abstract][Full Text] [Related]
29. Drug interaction between cyclosporine and mTOR inhibitors in experimental model of chronic cyclosporine nephrotoxicity and pancreatic islet dysfunction.
Piao SG; Bae SK; Lim SW; Song JH; Chung BH; Choi BS; Yang CW
Transplantation; 2012 Feb; 93(4):383-9. PubMed ID: 22267156
[TBL] [Abstract][Full Text] [Related]
30. A novel long acting DPP-IV inhibitor PKF-275-055 stimulates β-cell proliferation resulting in improved glucose homeostasis in diabetic rats.
Akarte AS; Srinivasan BP; Gandhi S
Biochem Pharmacol; 2012 Jan; 83(2):241-52. PubMed ID: 22015634
[TBL] [Abstract][Full Text] [Related]
31. Vildagliptin , a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin.
Forst T; Bramlage P
Expert Opin Pharmacother; 2014 Jun; 15(9):1299-313. PubMed ID: 24837407
[TBL] [Abstract][Full Text] [Related]
32. Protective Effects of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, against Cisplatin-Induced Nephrotoxicity in Mice.
Choi SH; Leem J; Lee IK
Mediators Inflamm; 2017; 2017():4139439. PubMed ID: 29317794
[TBL] [Abstract][Full Text] [Related]
33. The Dose-Dependent Organ-Specific Effects of a Dipeptidyl Peptidase-4 Inhibitor on Cardiovascular Complications in a Model of Type 2 Diabetes.
Moon JY; Woo JS; Seo JW; Lee A; Kim DJ; Kim YG; Kim SY; Lee KH; Lim SJ; Cheng XW; Lee SH; Kim W
PLoS One; 2016; 11(3):e0150745. PubMed ID: 26959365
[TBL] [Abstract][Full Text] [Related]
34. Combination of mangiferin and dipeptidyl peptidase-4 inhibitor sitagliptin improves impaired glucose tolerance in streptozotocin-diabetic rats.
Hou J; Zheng D; Fan K; Yu B; Xiao W; Ma J; Jin W; Tan Y; Wu J
Pharmacology; 2012; 90(3-4):177-82. PubMed ID: 22948814
[TBL] [Abstract][Full Text] [Related]
35. Vildagliptin selectively ameliorates GLP-1, GLUT4, SREBP-1c mRNA levels and stimulates β-cell proliferation resulting in improved glucose homeostasis in rats with streptozotocin-induced diabetes.
Akarte AS; Srinivasan BP; Gandhi S
J Diabetes Complications; 2012; 26(4):266-74. PubMed ID: 22626875
[TBL] [Abstract][Full Text] [Related]
36. Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury.
Chinda K; Palee S; Surinkaew S; Phornphutkul M; Chattipakorn S; Chattipakorn N
Int J Cardiol; 2013 Jul; 167(2):451-7. PubMed ID: 22285447
[TBL] [Abstract][Full Text] [Related]
37. Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes.
Gallwitz B
Drugs Today (Barc); 2007 Oct; 43(10):681-9. PubMed ID: 17987221
[TBL] [Abstract][Full Text] [Related]
38. Exendin-4 partly ameliorates - hyperglycemia-mediated tissue damage in lungs of streptozotocin-induced diabetic mice.
Oztay F; Sancar-Bas S; Gezginci-Oktayoglu S; Ercin M; Bolkent S
Peptides; 2018 Jan; 99():99-107. PubMed ID: 29225158
[TBL] [Abstract][Full Text] [Related]
39. Dipeptidyl peptidase-IV inhibition prevents blood-retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats.
Gonçalves A; Marques C; Leal E; Ribeiro CF; Reis F; Ambrósio AF; Fernandes R
Biochim Biophys Acta; 2014 Sep; 1842(9):1454-63. PubMed ID: 24769045
[TBL] [Abstract][Full Text] [Related]
40. Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a glucagon-like peptide-1 secretagogue.
Sangle GV; Lauffer LM; Grieco A; Trivedi S; Iakoubov R; Brubaker PL
Endocrinology; 2012 Feb; 153(2):564-73. PubMed ID: 22186413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
